Top Markets
Coin of the day
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVB
Classifica tra le azioni #99999
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the... Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
Prezzo delle azioni
$0.09933121
Capitalizzazione di mercato
$29.15K
Variazione (1 giorno)
0.57%
Variazione (1 anno)
449.49%
Paese
IE
Scambia Ovoca Bio plc (OVB)

Categoria

Ricavi di Ovoca Bio plc (OVB)
Ricavi nel Jun 2024 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Ovoca Bio plc, i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2023, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2022, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Ovoca Bio plc da 2001 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 0.00%
2001 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
$48.44B -
DK
$12.04B -
US
$14.34B -
US
$9.08B -
BE
$5.49B -
NL